165 related articles for article (PubMed ID: 38704786)
1. Prognostic value of combining clinical factors,
Lue KH; Chen YH; Chu SC; Lin CB; Wang TF; Liu SH
Ann Nucl Med; 2024 May; ():. PubMed ID: 38704786
[TBL] [Abstract][Full Text] [Related]
2. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
3. A comparison of 18 F-FDG PET-based radiomics and deep learning in predicting regional lymph node metastasis in patients with resectable lung adenocarcinoma: a cross-scanner and temporal validation study.
Lue KH; Chen YH; Chu SC; Chang BS; Lin CB; Chen YC; Lin HH; Liu SH
Nucl Med Commun; 2023 Dec; 44(12):1094-1105. PubMed ID: 37728592
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of
Agüloğlu N; Akyol M; Kömek H; Katgı N
Mol Imaging Radionucl Ther; 2022 Jun; 31(2):104-113. PubMed ID: 35770976
[TBL] [Abstract][Full Text] [Related]
5. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery.
Lee H; Choi YL; Kim HK; Choi YS; Kim H; Ahn MJ; Pyo HR; Choi JY
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686654
[TBL] [Abstract][Full Text] [Related]
9. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Predictive Values of
Hong IK; Lee JM; Hwang IK; Paik SS; Kim C; Lee SH
Cancer Manag Res; 2020; 12():6453-6465. PubMed ID: 32801885
[TBL] [Abstract][Full Text] [Related]
11. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
12. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
13.
Huang YE; Tsai YH; Huang YJ; Lung JH; Ho KW; Yen TC; Chan SC; Chen ST; Tsai MF; Hung MS
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326662
[TBL] [Abstract][Full Text] [Related]
14. Predicting EGFR mutation subtypes in lung adenocarcinoma using
Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
[TBL] [Abstract][Full Text] [Related]
15. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.
Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib.
Kus T; Aktas G; Sevinc A; Kalender ME; Yilmaz M; Kul S; Oztuzcu S; Oktay C; Camci C
Onco Targets Ther; 2015; 8():3749-56. PubMed ID: 26719702
[TBL] [Abstract][Full Text] [Related]
17. The Role of Histogram-Based Textural Analysis of
Önner H; Coşkun N; Erol M; Eren Karanis Mİ
Mol Imaging Radionucl Ther; 2022 Feb; 31(1):33-41. PubMed ID: 35114750
[TBL] [Abstract][Full Text] [Related]
18. Optimal
Zuo Y; Liu Q; Li N; Li P; Zhang J; Song S
Front Oncol; 2023; 13():1173355. PubMed ID: 37223682
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Combing Primary Tumor and Nodal Glycolytic-Volumetric Parameters of
Chen YH; Chu SC; Wang LY; Wang TF; Lue KH; Lin CB; Chang BS; Liu DW; Liu SH; Chan SC
Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34207763
[TBL] [Abstract][Full Text] [Related]
20. Volumetric and texture analysis of pretherapeutic
Werner RA; Bundschuh RA; Higuchi T; Javadi MS; Rowe SP; Zsótér N; Kroiss M; Fassnacht M; Buck AK; Kreissl MC; Lapa C
Endocrine; 2019 Feb; 63(2):293-300. PubMed ID: 30206772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
